EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, AGEN: Agenus Inc

15 Oct 25 17:14
LAST:

3.980

CHANGE:
 0.01		OPEN:
3.990		HIGH:
4.008		ASK:
3.730		VOLUME:
391.7K
CHG(%):
0.25		PREV:
3.970		LOW:
3.840		BID:
3.560		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 253.9904.0083.8403.980391.8K
14 Oct 253.9903.9903.8353.970356.1K
13 Oct 253.9804.0703.9244.050384.2K
10 Oct 254.2604.2603.9503.970327.1K
09 Oct 254.2304.3984.2204.250449.5K
08 Oct 254.1504.2304.1244.170351.6K
07 Oct 254.2004.3804.1204.250592.7K
06 Oct 254.1404.2104.0704.150406.2K
03 Oct 254.0004.3403.9204.140826.7K
02 Oct 253.9103.9603.8733.940289K

COMPANY PROFILE

Name:Agenus Inc
About:Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:3 Forbes Road, Lexington, MA, United States, 02421-7305
Website:https://www.agenusbio.com
CUSIP:037032109
CIK:0001098972
ISIN:US00847G8042
FIGI:BBG000C8SWQ9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:4.041.6%
MA10:4.092.7%
MA20:4.133.9%
MA50:4.379.7%
MA100:4.8321.2%
MA200:3.824.2%
STO9:2.34 
STO14:23.74
RSI14:53.28
WPR14:-67.50
MTM14:0.03
ROC14:0.01 
ATR:0.20 
Week High:4.4010.5%
Week Low:3.843.8%
Month High:4.8020.6%
Month Low:3.764.2%
Year High:7.3484.4%
Year Low:1.38188.4%
Volatility:71.90 

RECENT SPLITS

Date Ratio
12 Apr 20241-20
03 Oct 20111-6